Adhering to the concept of “consolidating the foundation, technological innovation, and sustainable development”, the company adheres to the path of industrialization of high-end specialty generic drugs in line with the international community. It currently has 22 wholly-owned and holding subsidiaries located in Shanghai, Guizhou, Liaoning, Jiangsu and Hainan. The company's main business products cover major diseases such as cardiovascular, oncology, orthopedics, pediatrics, gynecology, etc. The company is an enterprise focusing on the medical and health industry. It is involved in pharmaceutical R&D, production, sales and other businesses, as well as in the field of pharmaceutical investment. The company's product line includes: cardiovascular product line, anti-tumor product line, rheumatology and orthopedic disease product line, women's and children's product line, digestive system product line, burn product line, anti-infective product line, medical device product line, anti-inflammatory and analgesic product line.
No Data